pertuzumab,pembrolizumab,dostarlimab,talazoparib,durvalumab,trastuzumab,olaparib,paclitaxel,neratinib,cemiplimab,ganetespib,irinotecan,tucatinib
gsk,bms,amgen,astrazeneca,daiichi sankyo,merck,roche
['i-spy', 'breast']
 breast cancer #subtype redefinition using the i-spy2-990 data resource and response data over 10 drugs. very interesting... to read thinking about #asco2022 news!
Molecular Oncology. 
Precision Medicine. 
The view expressing are my own.